Development and Evaluation of Felbamate Loaded Solid Lipid Nanoparticles

Ramanuj Prasad Samal


Solid lipid nanoparticles (SLN’s) or lipid nano particles is typically sphere-shaped, with an average diameter of 1nm to 1000nm.  They are alternative carrier systems to tradition colloidal carriers, such as, emulsions, liposomes, and polymeric micro and nanoparticles. The main aim of the current research work is to prepare and optimize the Felbamate loaded solid lipid nanoparticles using by placket and burman design of experiments. SLN’s were prepared by microemulsion technique. Based on preliminary experiments and on literature, the influence of independent variable parameters selected were lipid (X1), surfactant (X2), and co-surfactant concentration(X3),aqueous phase volume(X4),magnetic stirrer rate (X5), probe sonication duration (X6), volume of beaker used for sonication (X7), volume of cold aqueous phase (X8) on the dependent variable such as average particle size (Y1) was studies. Other parameters, i.e., magnetic stirrer rate and probe sonication duration were not having a significant impact on particle size and their levels were kept constant for all the experiments. Magnetic stirrer rate has an impact on particle size and was included in the design. It was concluded from the study that the composition prepared with lipid concentration of 50 mg, surfactant concentration of 75 mg, Co-surfactant concentration of 0.75 ml, aqueous phase volume of 5 ml, magnetic stirring speed of 400 rpm, probe sonication duration 30 minutess, volume of beaker used for sonication 500 ml and volume of cold aqueous phase 30 ml has shown the smallest particle size of 165 nm

Full Text:



Rossella V, Salvatore G, Fulvia C, MariaAngela F, Rosanna DB, Guido M, Paolo B. Epilepsy in neurofibromatosis1. Journal of Child Neurology 2003; 18(5) 338–342.

Adam PO, David HG, Judith LZW. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 2013; 54(10): 1810–1814.

Clorinda A, Teresa M, Fernando P,Patricia F, Ricardo T. Okadaic acid induces epileptic seizures and hyperphosphorylation of the NR2B subunit of the NMDA receptor in rat hippocampus invivo. Experimental Neurology 2002; 177(1): 284–291.

Lucks JS, Muller RH. Medication vehicles made of solid lipid particles (solid lipid nanospheres SLN), in EP0000605497. 1996: Germany.

Saupe A, Wissing SA, Lenk A, Schmidt C Muller RH. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) – Structural investigations on two different carrier systems. Bio-Medical Material Engineering 2005; 15: 393–402.

Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs, International Journal of Pharmaceutics 2002; 242(1-2):121-8.

Jenning V, Thunemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. International Journal of Pharmaceutics 2000; 199(2): 167-77.

Jenning V, Mader K, Gohla S. Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a 1H-NMR study, International Journal of Pharmaceutics 2000; 205(1-2):15-21.

Muller RH. Lipid nanoparticles: recent advances, Advances in Drug Delivery Reviews 2007; 59(6):375-76.

Muller RH, Gohla S, Dingler A, Schneppe T. Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM), in Handbook of Pharmaceutical Controlled Release Technology Wise, D.L., Editor. 2000. p. 359-76.

Burdette David E, Sackellares J Chris. Felbamate Pharmacology and Use in Epilepsy, Clinical Neuropharmacology 1994; 17(5):389-402.

Vicki C, WilliamsA. Selective antagonism of the anticonvulsant effects of felbamate by glycine. European Journal of Pharmacology 1994; 256(2): R9-R10.

Giovambattista DS, Ennio O, Rosalia B, Umberto A, Angela DS. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. European Journal of Pharmacology 1994; 262(1-2): 11-19.

Nancy WK, Jill CG, Chi CC, Tammy DM. Subtype-Selective Antagonism of N-Methyl-D-Aspartate Receptors by Felbamate: Insights into the Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics 1999; 289 (2): 886-894.

Ticku MK, Kamatchi GL, Sofia RD. Effect of Anticonvulsant Felbamate on GABAA Receptor System. Epilepsia1991; 32: 389–391.

Swinyard EA, Sofia RD, Kupferberg HJ. Comparative Anticonvulsant Activity and Neurotoxicity of Felbamate and Four Prototype Antiepileptic Drugs in Mice and Rats. Epilepsia 1986; 27: 27–34


  • There are currently no refbacks.